Alberta Investment Management Corp holds $5.07 Million in
Biogen Inc. (NASDAQ:BIIB). Despite the company's
profit outlook falling short, it has beat estimates thanks to cost cuts and new drugs like Leqembi.
Biogen and Stoke Therapeutics have collaborated to develop
Zorevunersen for Dravet Syndrome treatment. Biogen's
2025 forecasts are affected by declining sales for MS drugs and a strong dollar.
FDA has accepted LEQEMBI's Biologics License for subcutaneous maintenance dosing for Early Alzheimer’s Disease. Biogen suffered a price hit after the earnings report. Its
stock is mutating into a value play.
Tim Power has been appointed as Head of Investor Relations. With a $81.96 Million position
Allianz Asset Management is a major player in Biogen. Biogen
Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal. Physics dating dumped by regulatory update in Bet for
Alzheimer's Disease in the EU. Biogen and Sage Therapeutics have clashed over an unsolicited nonbinding acquisition proposal from Biogen, rejected by Sage claiming the offer undervalues the company.
Biogen BIIB News Analytics from Wed, 22 May 2024 07:00:00 GMT to Sat, 22 Feb 2025 21:49:55 GMT -
Rating -1
- Innovation 2
- Information 7
- Rumor -3
